Used 2026 Hyundai Tucson SEL is Now Available at We Auto in Baton Rouge, LA
We Auto in Baton Rouge, LA, now offers a used 2026 Hyundai Tucson SEL, delivering modern features, strong safety technology,…
Brand Post
PureHealth Research Positions Supplements for Nervous System Support as Essential Tools for High Performers
MANASSAS, Va., Jan. 5, 2026 /PRNewswire/ — PureHealth Research announces their collection of supplements for nervous system support, designed for biohackers,…
The Unexpected Influencers Driving Technology, Travel and Wellness Trends in 2026
Four trends Canadians aged 55+ are setting as leading indicators for businesses and all Canadians TORONTO, Jan. 5, 2026 /CNW/…
IntBot to Debut First-Ever Unmanned CES Booth Run by a Robot; Humanoid “Nylo” Takes the Floor Solo
LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — CES 2026 — IntBot, the social robotics company with an active commercial fleet…
Destinus completes acquisition of Daedalean, accelerating next-generation AI for defense and civil aviation
ZÜRICH and AMSTERDAM, Jan. 5, 2026 /PRNewswire/ — Destinus Group BV has completed the acquisition of Daedalean AG, the Zürich-based…
BC.GAME Esports Complete 2026 CS2 Roster Upgrade, Sign SAW Core Trio
BELIZE City, Belize, Jan. 5, 2026 /PRNewswire/ — BC.GAME Esports today announced a roster upgrade for its Counter-Strike 2 (CS2) programme,…
Dowinx at CES 2026: User-Centered Ergonomic Innovation in Gaming Chairs
LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — Dowinx, a global brand in the ergonomic gaming furniture category, will attend CES…
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico’s AI-driven drug…
Lockin Debuts First-of-Its Kind Optical-Charging Smart Lock with Eternal, Zero-Maintenance Power at CES 2026
The market leader in vein recognition home security introduces AuraCharge™ technology in its new V7 Max smart lock, redefining the…
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
–The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety,…
↑